Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04669886 · ClinicalTrials.gov registry record

Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.

A clinical trial of Nephrolithiasis and Urosepsis, sponsored by University of Miami.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT04669886: Recruiting study of Nephrolithiasis and Urosepsis, sponsored by University of Miami.

NCT04669886 is a study of Nephrolithiasis and Urosepsis that is actively recruiting participants, run by University of Miami. The registered enrollment target is 150 participants, above the 115-participant average among 16 other Nephrolithiasis trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04669886, a study of Nephrolithiasis and Urosepsis, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The aim of the study is to establish an infectious risk stratification system based on pre-and post-operative blood endotoxin profile.

Primary Outcome

The endotoxin activity level assessed from blood samples will be categorized as low (\<0.40), intermediate (0.40-0.59) or high (≥0.60) endotoxin activity level. Analysis will be done via Endotoxin Activity Assay (EAA).

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-11-01
Est. Completion 2026-12-01
University of Miami

721 total trials

What NCT04669886 shows while recruiting

NCT04669886 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 16 other Nephrolithiasis trials with a reported enrollment target (30% higher).

The record links to 2 conditions, with Nephrolithiasis appearing as the primary indexed condition, and to 0 interventions.

NCT04669886 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04669886 about?

NCT04669886 is a clinical study titled "Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.". The aim of the study is to establish an infectious risk stratification system based on pre-and post-operative blood endotoxin profile.

What is the current status of trial NCT04669886?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2023-11-01. Estimated completion is 2026-12-01.

What conditions does trial NCT04669886 study?

This clinical trial studies the following conditions: Nephrolithiasis, Urosepsis.

Who is sponsoring clinical trial NCT04669886?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04669886 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nephrolithiasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04669886's enrollment target sits among peer trials

150 3rd of 16 higher than 13 of 16 other Nephrolithiasis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Nephrolithiasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04669886, the US trial registry maintained by the National Library of Medicine. NCT04669886 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.